OncoMed Pharmaceuticals Granted Fourth RSPO-LGR Pathway Patent in U.S.

OncoMed Pharmaceuticals (Nasdaq: OMED ), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the issuance of its fourth broad U.S. patent relating to antibodies that target the RSPO-LGR cancer stem cell pathway. The new patent, U.S. Patent No. 8,628,774, covers